More than 100,000 people in the United States suffer from carotides, the tiny blood-carrying molecules that carry oxygen to our bodies.
They are one of the key factors that keeps us alive and healthy, and researchers have been looking for ways to boost their production.
A few years ago, the research group Bio-Rad Research and Development (Brd) began developing a technique to make carotide-enriched blood.
Called bio-injection, it uses a cocktail of chemicals, including dimethylammonium bromide, or DMT, a common ingredient in perfumes and cosmetics.
The aim is to increase the production of carotine, the substance that carries oxygen to the body.
It can be injected directly into the bloodstream to treat people with carotidas.
The idea was that the compound would have an anti-inflammatory effect, helping to prevent inflammation in people with certain types of cancer.
The new treatment has been tested on mice with melanoma, a type of cancer that affects skin, and on patients with other types of cancers.
It was the first time scientists injected the compounds directly into patients’ blood, said Dr. Daniel Geller, an associate professor of medicine at the University of California, San Francisco.
Bio-Rad is hoping to commercialize the technology in the next five years.
Geller has been researching the use of caritin, a pigment found in the blood, to treat a wide range of conditions, including depression, migraines, heartburn and asthma.
He has a new company called Bio-Med.
Gellers co-inventor, Dr. Robert H. Geller III, is also on the Bio-Radioactive Solutions team at Bio-rad.
He and his co-founder, Dr., Jeffrey P. J. Brown, are also members of the advisory board at BioRad.
Brown has been working on the treatment for more than 20 years.
He said he has a long history of using his work to improve the health of people around the world.
“I am always finding new things that could help people,” Brown said.
Brown said that he and his colleagues have been working with patients and doctors to find the best ways to make it work.
He explained that the drug is an engineered version of an enzyme called cyclophosphamide synthase (CPSS), which helps regulate the production and utilization of collagen, the proteins that form the skin’s outer layer.
That protein is required for healthy skin.
“We can make collagen and get it into the blood,” Brown explained.
“We can also increase the amount of collagen in the body.”
The new drug, which is designed to be used by both adults and children, uses a synthetic molecule called dimethylimmonium tris(a)trifluoroacetate.
It is made from the same chemical that is used in paint and is also found in cosmetics.
When injected into the body, the drug works like a catalyst that boosts collagen production in the bloodstream.
Gellar said that his group is also working on a second compound that can be used in conjunction with the first drug.
The compound is a synthetic derivative of an older drug called dimethyl sulfoxide.
It has been shown to have an antitumor effect in animal models.
“This compound is very powerful,” Brown noted.
“It’s probably the most potent compound out there.”
He said the company plans to introduce the drug into the clinic within the next few months.
The drug is being tested in a trial that is being run by a major hospital in the US, Kaiser Permanente, where it is being used to treat patients with melanomas.
A spokeswoman for Kaiser said that the company has not yet decided whether the drug will be approved for clinical use.